BioCentury | Jul 23, 2015
Tools & Techniques

Gene therapy's coming of age

...uniQure N.V.; Voyager Therapeutics Inc. AAV5 AAV Blood; Brain; Liver; Synovium Phase I Arthrogen B.V.; Digna Biotech S.L....
BioCentury | Oct 28, 2014
Clinical News

One-year follow up for uniQure's liver gene therapy

...The gene therapy has Orphan Drug designation in the EU. The trial was conducted by Digna Biotech S.L....
BioCentury | Jan 13, 2014
Product Development

Niche play on TGF beta

...as a ligand trap to inhibit members of the TGF beta superfamily such as TGFB1. Digna Biotech S.L....
...LSE:AZN; NYSE:AZN), London, U.K. Boston Children's Hospital , Boston, Mass. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Digna Biotech S.L....
BioCentury | Mar 21, 2013
Targets & Mechanisms

Understanding fibrosis

...ACE-536 Hematology Anemia and thalassemia Phase II Digna Biotech S.L. Disitertide (P144) Autoimmune disease Scleroderma Phase II Digna Biotech...
...Dermatology Scars and wrinkles Phase II Yuhan Corp. YH14618 Musculoskeletal disease Cartilage repair Phase I/II Digna Biotech...
BioCentury | Nov 29, 2012
Distillery Therapeutics

Indication: Cancer

...Ongoing work includes exploring the synergy of the triple fusion protein with other cancer therapeutics. Digna Biotech S.L....
...development. SciBX 5(46); doi:10.1038/scibx.2012.1203 Published online Nov. 29, 2012 Patent applications filed; exclusively licensed to Digna Biotech...
BioCentury | Jan 2, 2012
Clinical News

Disitertide: Phase IIa data

...regained exclusive rights to disitertide from Isdin S.A. (Barcelona, Spain) (see BioCentury, Nov. 21, 2011). Digna Biotech S.L....
BioCentury | Nov 21, 2011
Company News

Digna Biotech, Isdin deal

...and Isdin partnered to develop P144 though the open-label extension of the Phase IIa trial. Digna Biotech S.L....
BioCentury | Sep 26, 2011
Clinical News

Cardiotrophin-1 regulatory update

...the prevention of ischemic/reperfusion injury associated with solid organ transplantation. Biotecnol S.A. , Oeiras, Portugal Digna Biotech S.L....
BioCentury | Aug 25, 2011
Cover Story

Cardiotrophin workout

...energy utilization and appetite. 1 The findings open up a new indication for university spinout Digna Biotech S.L....
...doi:10.1038/scibx.2011.922 Published online Aug. 25, 2011 Companies and Institutions Mentioned Biotecnol S.A. , Oeiras, Portugal Digna Biotech S.L....
BioCentury | Aug 25, 2011
Distillery Therapeutics

Indication: Metabolic disease

...Next steps include characterizing the effects of CT-1 treatment on cardiac muscle and cardiovascular endpoints. Digna Biotech S.L....
...online Aug. 25, 2011 Patent pending on use of CT-1 in metabolic indications; licensed to Digna Biotech...
Items per page:
1 - 10 of 21
BioCentury | Jul 23, 2015
Tools & Techniques

Gene therapy's coming of age

...uniQure N.V.; Voyager Therapeutics Inc. AAV5 AAV Blood; Brain; Liver; Synovium Phase I Arthrogen B.V.; Digna Biotech S.L....
BioCentury | Oct 28, 2014
Clinical News

One-year follow up for uniQure's liver gene therapy

...The gene therapy has Orphan Drug designation in the EU. The trial was conducted by Digna Biotech S.L....
BioCentury | Jan 13, 2014
Product Development

Niche play on TGF beta

...as a ligand trap to inhibit members of the TGF beta superfamily such as TGFB1. Digna Biotech S.L....
...LSE:AZN; NYSE:AZN), London, U.K. Boston Children's Hospital , Boston, Mass. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Digna Biotech S.L....
BioCentury | Mar 21, 2013
Targets & Mechanisms

Understanding fibrosis

...ACE-536 Hematology Anemia and thalassemia Phase II Digna Biotech S.L. Disitertide (P144) Autoimmune disease Scleroderma Phase II Digna Biotech...
...Dermatology Scars and wrinkles Phase II Yuhan Corp. YH14618 Musculoskeletal disease Cartilage repair Phase I/II Digna Biotech...
BioCentury | Nov 29, 2012
Distillery Therapeutics

Indication: Cancer

...Ongoing work includes exploring the synergy of the triple fusion protein with other cancer therapeutics. Digna Biotech S.L....
...development. SciBX 5(46); doi:10.1038/scibx.2012.1203 Published online Nov. 29, 2012 Patent applications filed; exclusively licensed to Digna Biotech...
BioCentury | Jan 2, 2012
Clinical News

Disitertide: Phase IIa data

...regained exclusive rights to disitertide from Isdin S.A. (Barcelona, Spain) (see BioCentury, Nov. 21, 2011). Digna Biotech S.L....
BioCentury | Nov 21, 2011
Company News

Digna Biotech, Isdin deal

...and Isdin partnered to develop P144 though the open-label extension of the Phase IIa trial. Digna Biotech S.L....
BioCentury | Sep 26, 2011
Clinical News

Cardiotrophin-1 regulatory update

...the prevention of ischemic/reperfusion injury associated with solid organ transplantation. Biotecnol S.A. , Oeiras, Portugal Digna Biotech S.L....
BioCentury | Aug 25, 2011
Cover Story

Cardiotrophin workout

...energy utilization and appetite. 1 The findings open up a new indication for university spinout Digna Biotech S.L....
...doi:10.1038/scibx.2011.922 Published online Aug. 25, 2011 Companies and Institutions Mentioned Biotecnol S.A. , Oeiras, Portugal Digna Biotech S.L....
BioCentury | Aug 25, 2011
Distillery Therapeutics

Indication: Metabolic disease

...Next steps include characterizing the effects of CT-1 treatment on cardiac muscle and cardiovascular endpoints. Digna Biotech S.L....
...online Aug. 25, 2011 Patent pending on use of CT-1 in metabolic indications; licensed to Digna Biotech...
Items per page:
1 - 10 of 21